Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Table 2

PD-L1 IHC assay systems as companion and complementary diagnostic assays for NSCLC treatment using anti-PD-1/PD-L1 agents.

Assay system	Source and antibody clonality	Therapeutic antibody	Type of tissue	Detection systems required	Instrument	TPS	Company	Cancer
PD-L1 IHC 28-8 pharmDx Dako	Rabbit monoclonal	Nivolumab	FFPE	Autostainer Link 48	EnVision FLEX visualization system	Tumor cell membrane staining	Dako Autolink 48	Nonsquamous NSCLC
PD-L1 IHC 22C3 pharmDx Dako	Mouse monoclonal	Pembrolizumab	FFPE	Autostainer Link 48	EnVision FLEX visualization system	Tumor cell membrane staining	Dako Autolink 48	NSCLC
Ventana PD-L1 (SP142) assay	Rabbit monoclonal	Atezolizumab	FFPE	OptiView Amplification	Ventana BenchMark ULTRA	Tumor cell membrane and immune cell staining	Ventana Ultra	NSCLC
Ventana PD-L1 (SP263)	Rabbit monoclonal	Durvalumab	FFPE	OptiView Amplification	Ventana BenchMark ULTRA	Tumor cell membrane staining	Ventana Ultra	NSCLC

FFPE: formalin-fixed paraffin-embedded; IC: immune cells; NSCLC: non-small-cell lung cancer; PD-1: programmed death-1; PD-L1: programmed death-ligand 1; TC: tumor cells; TPS: tumor proportion score.